Genta Inc. of San Diego announced Tuesday that on Dec. 29 itfiled an investigational new drug application (IND) with FDA tobegin testing a topical, non-steroidal anti-inflammatory drug totreat psoriasis, acne and atopic dermatitis. The filing wasGenta's fifth IND submission for a conventional dermatologicaldrug completed in 1992. Genta's stock (NASDAQ:GNTA) closedTuesday at $10.50, up $1.50 per share.
(c) 1997 American Health Consultants. All rights reserved.